CDMOs offering CMC Analytical Development with Cell Therapy in United States

22 matching organizations

• AGC Biologics

  Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.

• Akron Bio

  Akron Bio manufactures cGMP-compliant recombinant proteins, media, buffers, and transfection reagents for cell and gene therapy companies. Services span process development, fill-finish, and custom ancillary product manufacturing.

• Aldevron

  Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.

• Andelyn Biosciences

  CDMO specializing in plasmid DNA and AAV viral vector manufacturing for cell and gene therapy, with digital-first platform emphasizing data integrity and collaboration.

• Asimov

  Asimov provides cell line development, upstream process development, and viral vector manufacturing services powered by proprietary synthetic biology platforms (CHO Edge, LV Edge, AAV Edge, RNA Edge) that deliver high-titer, stable cell lines and production systems for biologics, cell therapies, and gene therapies.

• Boston Institute of Biotechnology, LLC

  Full-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L.

• Catalent

  Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.

• Cellares

  Cellares operates a global network of Smart Factories delivering integrated development and manufacturing (IDMO) services for cell therapies, with proprietary Cell Shuttle® and Cell Q™ platforms enabling cGMP-compliant, automated manufacturing and quality control at clinical and commercial scale.

• Cellipont Bioservices

  Cellipont Bioservices is a cell therapy CDMO offering end-to-end development, analytical, and cGMP manufacturing services for autologous, allogeneic, CAR-T, and iPSC-derived therapies from preclinical through commercial stages.

• Charles River Laboratories

  Charles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.

• ElevateBio

  Advanced therapies CDMO providing discovery, process development, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA, and gene editing programs from preclinical through commercial scale.

• FUJIFILM Biotechnologies

  CDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.

• Genezen

  Viral vector CDMO specializing in AAV, lentiviral, and retroviral manufacturing for gene and cell therapies, with cGMP facilities in Indiana and Massachusetts supporting preclinical through commercial-scale production.

• Kincell Bio

  Leading cell therapy CDMO delivering GMP manufacturing, analytics, and CMC strategy from early development through commercial launch across purpose-built U.S. facilities.

• Made Scientific

  Cell therapy CDMO offering end-to-end development, GMP manufacturing, and regulatory support from preclinical through commercial scale, with specialized expertise in T cells, NK cells, MSCs, iPSCs, and other cell modalities.

• Minaris Advanced Therapies

  Pure-play cell and gene therapy CDMO with over 25 years of GMP manufacturing, process development, and biosafety testing expertise. Serves advanced therapy innovators globally from early stage through commercialization.

• National Resilience

  End-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.

• Oxford Biomedica

  Global viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.

• Pharmaron

  Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.

• Pluri

  Full-service CDMO specializing in cell therapy manufacturing with GMP facilities, proprietary packed-bed expansion technology, and regulatory approvals from FDA, EMA, PMDA, and other key agencies for clinical-stage production.

• Porton Advanced

  End-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.

• Syngene International

  Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.

Markdown mirror: /explore/svc_analytical_dev_cdmo/mod_cell_therapy/us.md